158 related articles for article (PubMed ID: 11347977)
1. Trypsinogen-1, -2 and tumour-associated trypsin-inhibitor in bile and biliary tract tissues from patients with biliary tract diseases and pancreatic carcinomas.
Hedström J; Haglund C; Leinonen J; Nordling S; Stenman UH
Scand J Clin Lab Invest; 2001 Apr; 61(2):111-8. PubMed ID: 11347977
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer.
Hotakainen K; Bjartell A; Sankila A; Järvinen R; Paju A; Rintala E; Haglund C; Stenman UH
Int J Oncol; 2006 Jan; 28(1):95-101. PubMed ID: 16327984
[TBL] [Abstract][Full Text] [Related]
3. Tumour-associated trypsin inhibitor TATI is a prognostic marker in colorectal cancer.
Koskensalo S; Hagström J; Louhimo J; Stenman UH; Haglund C
Oncology; 2012; 82(4):234-41. PubMed ID: 22508321
[TBL] [Abstract][Full Text] [Related]
4. Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases.
Haglund C; Huhtala ML; Halila H; Nordling S; Roberts PJ; Scheinin TM; Stenman UH
Br J Cancer; 1986 Aug; 54(2):297-303. PubMed ID: 3741764
[TBL] [Abstract][Full Text] [Related]
5. Biochemistry and clinical role of trypsinogens and pancreatic secretory trypsin inhibitor.
Paju A; Stenman UH
Crit Rev Clin Lab Sci; 2006; 43(2):103-42. PubMed ID: 16517420
[TBL] [Abstract][Full Text] [Related]
6. Biology and function of tumor-associated trypsin inhibitor, TATI.
Stenman UH; Koivunen E; Itkonen O
Scand J Clin Lab Invest Suppl; 1991; 207():5-9. PubMed ID: 1780691
[TBL] [Abstract][Full Text] [Related]
7. Serum trypsinogen-2 and trypsin-2-alpha(1)-antitrypsin complex in malignant and benign digestive-tract diseases. Preferential elevation in patients with cholangiocarcinomas.
Hedström J; Haglund C; Haapiainen R; Stenman UH
Int J Cancer; 1996 May; 66(3):326-31. PubMed ID: 8621252
[TBL] [Abstract][Full Text] [Related]
8. Tumour-associated trypsin inhibitor and tumour-associated trypsin.
Stenman UH
Scand J Clin Lab Invest Suppl; 1990; 201():93-101. PubMed ID: 2244188
[TBL] [Abstract][Full Text] [Related]
9. Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum.
Paju A; Vartiainen J; Haglund C; Itkonen O; von Boguslawski K; Leminen A; Wahlström T; Stenman UH
Clin Cancer Res; 2004 Jul; 10(14):4761-8. PubMed ID: 15269150
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
Paju A; Hotakainen K; Cao Y; Laurila T; Gadaleanu V; Hemminki A; Stenman UH; Bjartell A
Eur Urol; 2007 Dec; 52(6):1670-9. PubMed ID: 17306443
[TBL] [Abstract][Full Text] [Related]
11. Co-expression of trypsin and tumour-associated trypsin inhibitor (TATI) in colorectal adenocarcinomas.
Solakidi S; Tiniakos DG; Petraki K; Stathopoulos GP; Markaki I; Androulakis G; Sekeris CE
Histol Histopathol; 2003 Oct; 18(4):1181-8. PubMed ID: 12973686
[TBL] [Abstract][Full Text] [Related]
12. Tumor-associated trypsin inhibitor (TATI) and tumor-associated trypsin-2 (TAT-2) predict outcomes in gastric cancer.
Kasurinen A; Laitinen A; Kokkola A; Stenman UH; Böckelman C; Haglund C
Acta Oncol; 2020 Jun; 59(6):681-688. PubMed ID: 32124669
[No Abstract] [Full Text] [Related]
13. Tumor-associated trypsin inhibitor in pancreatic diseases.
Aroasio E; Piantino P
Scand J Clin Lab Invest Suppl; 1991; 207():71-3. PubMed ID: 1723534
[TBL] [Abstract][Full Text] [Related]
14. Concentration of tumor-associated trypsin inhibitor (TATI) in pleural effusions.
Klockars M; Pettersson T; Fröseth B; Selroos O; Stenman UH
Chest; 1990 Nov; 98(5):1159-64. PubMed ID: 2225961
[TBL] [Abstract][Full Text] [Related]
15. Immunocytochemical distribution of trypsinogen and pancreatic secretory trypsin inhibitor in normal and neoplastic tissues in man.
Marks WH; Ohlsson K; Polling A
Scand J Gastroenterol; 1984 Jul; 19(5):673-6. PubMed ID: 6382569
[TBL] [Abstract][Full Text] [Related]
16. Biliary immunoreactive trypsin in man.
Lake-Bakaar G; Dooley J
Hepatogastroenterology; 1987 Jun; 34(3):103-5. PubMed ID: 3038717
[TBL] [Abstract][Full Text] [Related]
17. TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer.
Medl M; Ogris E; Peters-Engl C; Leodolter S
Br J Cancer; 1995 May; 71(5):1051-4. PubMed ID: 7734298
[TBL] [Abstract][Full Text] [Related]
18. Effects of radiation therapy on tissue and serum concentrations of tumour associated trypsin inhibitor and their prognostic significance in rectal cancer patients.
Gaber A; Stene C; Hotakainen K; Nodin B; Palmquist I; Bjartell A; Stenman UH; Jeppsson B; Johnson LB; Jirström K
Radiat Oncol; 2011 Aug; 6():100. PubMed ID: 21864386
[TBL] [Abstract][Full Text] [Related]
19. High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer.
Wiksten JP; Lundin J; Nordling S; Kokkola A; Stenman UH; Haglund C
Histopathology; 2005 Apr; 46(4):380-8. PubMed ID: 15810949
[TBL] [Abstract][Full Text] [Related]
20. Activation of telomerase and its diagnostic application in biopsy specimens from biliary tract neoplasms.
Niiyama H; Mizumoto K; Kusumoto M; Ogawa T; Suehara N; Shimura H; Tanaka M
Cancer; 1999 May; 85(10):2138-43. PubMed ID: 10326691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
